The first meeting of the ACTTD was held and its role was to brief the ACVSB about the decision on whether to introduce anti HCV screening. Read more about The first meeting of the ACTTD was held and its role was to brief the ACVSB about the decision on whether to introduce anti HCV screening.
An Advisory Committee on the Virological Safety of Blood discussed cases of post-transfusion hepatitis discovered through HCV screening, and second generation trials of HCV tests conducted with Ortho and Abbott. Read more about An Advisory Committee on the Virological Safety of Blood discussed cases of post-transfusion hepatitis discovered through HCV screening, and second generation trials of HCV tests conducted with Ortho and Abbott.
The Advisory Committee on Virological Safety of Blood tabled a proposal on counselling of donors who tested anti-HCV positive and proposed to convene a meeting to consider and provide recommendations. Read more about The Advisory Committee on Virological Safety of Blood tabled a proposal on counselling of donors who tested anti-HCV positive and proposed to convene a meeting to consider and provide recommendations.
Dr Tedder prepared a preliminary report on the samples tested which showed how reactive the Abbott and Ortho testing were. Read more about Dr Tedder prepared a preliminary report on the samples tested which showed how reactive the Abbott and Ortho testing were.
A proposal for study of donations in three RTCs, Glasgow, Newcastle and North London, was agreed to be coordinated by Dr Gunson and the proposal stated that donors who tested anti-HCV positive were to be interviewed by a member of the medical staff to take medical history and arrange liver function tests. Read more about A proposal for study of donations in three RTCs, Glasgow, Newcastle and North London, was agreed to be coordinated by Dr Gunson and the proposal stated that donors who tested anti-HCV positive were to be interviewed by a member of the medical staff to take medical history and arrange liver function tests.
In a letter to Dr Rejman, Professor Arie Zuckerman stated that despite the projected costs of the screening test, the introduction of screening could not be delayed much beyond FDA approval considering the overall morbidity of chronic non-A non-B Hepatitis (including apparently autoimmune liver disease and hepatocellular carcinoma), and litigation which would be indefensible. Read more about In a letter to Dr Rejman, Professor Arie Zuckerman stated that despite the projected costs of the screening test, the introduction of screening could not be delayed much beyond FDA approval considering the overall morbidity of chronic non-A non-B Hepatitis (including apparently autoimmune liver disease and hepatocellular carcinoma), and litigation which would be indefensible.
Dr Lane wrote to Dr Rejman that the presence of antibody for Hepatitis C was not necessarily a marker of infectivity in HCV screening. However, Dr Gunson and the ACTTD were reporting the opposite of this, which Dr Mortimer and Professor Cash appeared to endorse. Read more about Dr Lane wrote to Dr Rejman that the presence of antibody for Hepatitis C was not necessarily a marker of infectivity in HCV screening. However, Dr Gunson and the ACTTD were reporting the opposite of this, which Dr Mortimer and Professor Cash appeared to endorse.
Dr Tuddenham wrote to John Canavan to support the move to evaluate the test based on detection of antibody to polypeptide synthesised by recombinant yeast clones of the HCV virus. This is because screening donor blood by such an assay could reduce the transmission rate of non-A non-B Hepatitis in single donor products and in some pooled plasma derivatives. Read more about Dr Tuddenham wrote to John Canavan to support the move to evaluate the test based on detection of antibody to polypeptide synthesised by recombinant yeast clones of the HCV virus. This is because screening donor blood by such an assay could reduce the transmission rate of non-A non-B Hepatitis in single donor products and in some pooled plasma derivatives.
Denmark, Sweden and Finland were trialling the Chiron/Ortho anti-HCV test, and several other countries were planning to do so. Read more about Denmark, Sweden and Finland were trialling the Chiron/Ortho anti-HCV test, and several other countries were planning to do so.
ACVSB met for the first time on 4 April 1989, chaired by Dr Harris. ACVSB's role was to give advice to the UK health ministers and would focus on the major policy issues with the implementation of the policy being for others. The issue of anti-HCV testing was not covered specifically. Read more about ACVSB met for the first time on 4 April 1989, chaired by Dr Harris. ACVSB's role was to give advice to the UK health ministers and would focus on the major policy issues with the implementation of the policy being for others. The issue of anti-HCV testing was not covered specifically.